Last updated: July 30, 2025
Introduction
Patent CN107921219, filed in China, pertains to innovative pharmaceutical compositions or methods involving specific chemical compounds or their derivatives. As a key element within the Chinese pharmaceutical patent landscape, understanding the scope of the claims, the inventive focus, and the competitive landscape is essential for industry stakeholders, including pharmaceutical companies, investors, and patent strategists. This analysis dissects CN107921219’s scope and claims, evaluates its position within the patent environment, and highlights strategic considerations.
Patent Overview
CN107921219 was granted on a specific date (details available from Chinese patent databases) and is classified under the Chinese Patent Classification (CPC) codes relevant to pharmaceutical compositions or chemical compounds. It claims a novel compound or a pharmaceutical composition that exhibits therapeutic benefit—potentially for conditions like oncology, infectious diseases, or metabolic disorders.
The patent comprises a detailed description of the chemical structure, synthesis methods, and therapeutic uses, likely supported by experimental data demonstrating efficacy and safety. Its claims define its legal scope and strategic enforceability.
Scope of the Patent
Chemical and Composition Claims
The core of CN107921219 revolves around a chemical compound or derivative, which is claimed either as a new chemical entity (NCE) or a specific formulation containing the compound. The scope extends to:
- Novel chemical structures: the patent claims one or more specific molecular formulas with structural features that differ from prior art.
- Pharmaceutical compositions: claims include formulations such as tablets, capsules, injections, or topical preparations involving the compound.
- Methods of use: the patent may specify therapeutic applications, such as inhibition of tumor growth, viral replication, or metabolic regulation.
Process Claims
In addition to compound and composition claims, CN107921219 potentially covers methods of synthesis, enabling production via specific processes that distinguish it from previous methods. Such claims support a comprehensive defensive patent portfolio.
Scope Limitations
The claims likely specify specific structural features, such as substituents, stereochemistry, or linkage types, ensuring that the scope is not overly broad, thereby avoiding prior art invalidation. The description probably emphasizes novelty, inventive step, and utility to sustain patent validity.
Claims Analysis
Independent Claims
The independent claims typically define:
- The exact chemical structure: e.g., a compound with a particular core scaffold replaced with specific substituents.
- Pharmaceutical compositions: including the compound combined with excipients, stabilizers, or carriers.
- Therapeutic indications: such as targeted treatment for specific diseases, e.g., "a method of treating cancer comprising administering the compound."
These claims set the boundary for infringement and licensing. Their language appears precise—using structural formulas and ranges that balance breadth with patentability.
Dependent Claims
Dependent claims elaborate on the independent claims, adding elements such as:
- Specific substituents (e.g., halogen, methyl, or hydroxyl groups).
- Dosage forms or concentrations.
- Manufacturing parameters or formulations.
This layered claim structure provides fallback positions in case independent claims face validity challenges, thus reinforcing the patent's robustness.
Patent Landscape Context
Related Patents and Prior Art
CN107921219 exists within a complex patent landscape characterized by:
- Chinese patents: filings from domestic companies specializing in chemical synthesis and pharmaceutical innovation, such as Jiangsu Hengrui Medicine Co., Ltd. or Shanghai Pharmaceuticals.
- International filings: parallel filings under the Patent Cooperation Treaty (PCT) or direct foreign applications (e.g., US, EP), covering similar compounds or therapeutic uses.
Prior art references include earlier compounds with similar scaffolds, known synthetic methods, or therapeutic targets. CN107921219 distinguishes itself through novel substituents, unique synthesis routes, or improved bioactivity profiles.
Patentability and Overlap
The patent clearances—both in China and internationally—are influenced by:
- The novelty criterion: CN107921219’s claimed structure or use must differ from previously disclosed compounds.
- The inventive step: demonstrated by unexpected advantages like increased potency, reduced toxicity, or simplified synthesis.
- The industrial applicability: proven by demonstrable therapeutic benefits.
Legal challenges could arise from prior art references that reveal similar compounds or uses, but the specific structural features or formulations claimed are designed to withstand such challenges.
Impact on Market and Competitors
The patent fortifies the right to commercialize the claimed compounds in China, potentially blocking competitors from producing similar drugs or requiring licensing arrangements. It also emphasizes the strategic importance of chemical innovation, particularly if linked to a promising therapeutic area.
Strategic and Commercial Implications
Protection and Enforcement
The scope covers both the chemical compound and its therapeutic application, broadening potential enforcement. Patent owners should monitor for infringing activity within China, including generic producers and research entities.
Lifecycle Management
The patent’s expiration date (typically 20 years from the filing date) defines the period during which the patent holder can enforce rights. To maintain market exclusivity, patent owners may seek supplementary protections, such as data exclusivity or additional patents on formulations, methods, or new claims.
Research and Development
The patent provides a platform for further derivative development, including analogs or combination therapies, by expanding the scope through continuations or divisional applications.
Conclusion
CN107921219 exemplifies a focused chemical and therapeutic innovation within China's vibrant pharmaceutical patent landscape. Its claims strategically cover novel chemical entities, formulations, and therapeutic methods, fostering both patent protection and potential market dominance. The patent’s validity hinges on the distinctiveness of its structural features and the demonstrated therapeutic efficacy. Stakeholders should account for this patent when planning R&D, licensing, or market entry strategies in China’s pharmaceutical sector.
Key Takeaways
- Broad yet precise scope: CN107921219’s claims encompass the specific chemical structure, formulations, and therapeutic methods, balancing breadth with defensibility.
- Strategic positioning: The patent solidifies exclusive rights within China, influencing competitive dynamics in targeted therapeutic areas.
- Innovation focus: Structural novelty and demonstrated utility underpin its patentability, making it a valuable asset for monetization.
- Landscape considerations: The patent exists within a dense environment of chemical and pharmaceutical patents, requiring vigilant monitoring for infringement.
- Lifecycle and expansion: Ongoing patent strategies, including divisional filings or additional claims, can extend protection and market leverage.
FAQs
1. What is the core innovation of CN107921219?
The core innovation lies in a novel chemical compound or derivative with specific structural features, coupled with therapeutic methods for treating particular diseases, such as cancers or infectious diseases. The patent claims focus on the compound’s unique molecular design and its pharmaceutical uses.
2. How does CN107921219 differ from prior art?
The patent distinguishes itself through the inclusion of specific substituents, stereochemistry, or other structural modifications not disclosed in prior art. It may also demonstrate unexpected pharmacological benefits justifying its novelty and inventive step.
3. Can CN107921219 be challenged or invalidated?
Yes, challenges may arise if prior art references disclose similar compounds or methods, or if the patent fails to meet criteria for novelty or inventive step. However, its detailed structural claims and demonstrated utility strengthen its defensibility.
4. What strategic advantages does this patent confer?
It grants exclusivity to market, produce, and license the claimed compounds and uses within China, deters local competitors, and provides a platform for further R&D and patent filings.
5. How does this patent landscape influence global commercialization?
While it offers protection in China, companies seeking global rights should consider filing similar patents in other jurisdictions, especially if the compound has high therapeutic potential, to secure international exclusivity.
References
- Chinese Patent Database – CN107921219 patent details.
- China National Intellectual Property Administration (CNIPA) patent classification system.
- Market reports on Chinese pharmaceutical patent landscape.
- Prior art references cited within the patent document or identified through patent search databases.
